Bh

Periodontal diseases like periodontitis and gingivitis are common oral health issues that can worsen without early detection and care, potentially leading to gum inflammation, tooth loss, and reduced quality of life. This research evaluates an online self-assessment tool designed to help adults identify their risk of periodontal disease by comparing questionnaire results to clinical periodontal exams in the Saudi population. The study aims to measure how well the tool agrees with and accurately reflects the clinical periodontal risk categories of low, medium, and high. Participants will first complete an online questionnaire about their oral health symptoms, dental history, and hygiene habits. During the same visit, they will receive a clinical periodontal exam by a trained clinician, which serves as the reference standard to categorize their periodontal risk. This observational study does not include any treatment or preventive interventions, focusing solely on data collection through the questionnaire and clinical exam. Throughout the visit, participants provide data that researchers use to compare the self-assessment tool's risk classification against the clinical results. The study measures agreement, diagnostic accuracy, sensitivity, specificity, and overall performance of the self-assessment tool. Risks are minimal and may include mild discomfort or minor bleeding during the exam. Confidentiality is maintained by using study IDs and secure data storage. The findings aim to improve early detection of periodontal risk and support preventive oral health care efforts.

Researchers are conducting a long-term, multinational registry study to observe patients with generalized myasthenia gravis (gMG) who are treated with Alexion complement C5 inhibition therapies, including eculizumab (Soliris4) and ravulizumab (Ultomiris4). The goal is to collect data on clinical outcomes and safety over time to better understand the effects of these therapies in real-world settings. Participants' past medical histories and gMG treatment records will be reviewed at enrollment. After joining the registry, data will be collected prospectively during routine clinical care visits and through patient-reported outcomes. This data will be entered into an electronic system and collected for up to five years following enrollment. Participants will be involved through regular clinical care, with ongoing collection of clinical and safety information. The main outcome measured is the change in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score over approximately five years. This long-term follow-up allows researchers to monitor disease progression, treatment effects, and safety in a real-world patient population.

Chronic Obstructive Pulmonary Disease (COPD) is a major global health issue causing significant illness and death, especially in low- and middle-income countries. It involves a progressive decline in lung function with frequent worsening events called exacerbations, which accelerate disease progression and increase mortality risk. Current guidelines recommend assessing lung function, exacerbation history, and patient symptoms to guide treatment, including triple therapy with inhaled corticosteroids, long-acting muscarinic antagonists, and long-acting beta-agonists for patients with persistent symptoms and frequent exacerbations. This study focuses on evaluating the use of Breztri/Trixeo (BGF), a fixed-dose triple combination inhaler, in real-world settings across various global regions to better understand its impact on clinical and patient-reported outcomes over 12 months. The study is an international, multicenter, observational cohort design enrolling adults with moderate to severe COPD who have been prescribed BGF but have not yet started treatment. Patients will be followed for up to 52 weeks with visits at baseline, 12, 26, and 52 weeks. All treatments and assessments are conducted according to routine care by the patients' physicians without study intervention. The aim is to observe changes in COPD health status, measured by the COPD Assessment Test (CAT) and other patient-reported outcomes, as well as clinical outcomes such as exacerbation rates and lung function. The study includes diverse populations from Latin America, Asia, and the Middle East and Africa to gather broadly applicable real-world evidence. Participants will complete questionnaires and undergo routine clinical evaluations during scheduled visits. Researchers will collect data on demographics, medical history, lung function tests, exacerbations, medication use, and patient satisfaction with inhaler devices. The primary outcome is the change in CAT score after 12 weeks of BGF treatment, with secondary assessments at later time points and evaluation of exacerbation frequency and lung function parameters. The study will also monitor safety and treatment discontinuation, providing valuable insights into the effectiveness and patient experience with BGF in everyday clinical practice.